Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus FOLFIRI in second-line mCRC
NCT00339183Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2006
- Primary completion
- Apr 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of panitumumab in metastatic colorectal cancer (mCRC), sponsored by Amgen. Started Jun 2006; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00339183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00339183.